VO 2 Peak: The Emerging End Point For Cardiovascular Outcome Trials in Nephrology

Area of Science:

• Nephrology
• Cardiology
• Clinical Trials

Background:

• Cardiovascular outcome trials in chronic kidney disease (CKD) face significant challenges.
• Traditional endpoints in CKD cardiovascular trials often lack sensitivity or relevance.
• Limitations in endpoint selection impede the demonstration of treatment benefits in this population.

Purpose of the Study:

• To highlight the potential of Cardiopulmonary Exercise Testing (CPET) and its derived functional endpoints in nephrology clinical trials.
• To advocate for the adoption of VO2Peak as a primary endpoint in cardiovascular trials involving CKD patients.
• To explore how CPET-derived endpoints can enhance patient-centered research and facilitate regulatory approval.

Main Methods:

• Review of current challenges in CKD cardiovascular outcome trials.
• Introduction of Cardiopulmonary Exercise Testing (CPET) as an advanced technology.
• Discussion of VO2Peak as a robust measure of cardiovascular functional capacity.

Main Results:

• CPET provides a powerful tool for assessing functional capacity in CKD patients.
• VO2Peak, quantified by CPET, is recognized as a gold standard index.
• The Food and Drug Administration (FDA) has approved interventions using VO2Peak as an endpoint in other fields.

Conclusions:

• CPET-derived functional endpoints, particularly VO2Peak, offer a promising solution for CKD cardiovascular trials.
• Implementing VO2Peak can lead to more patient-centered trials and support regulatory decision-making.
• This approach presents an exciting opportunity to advance clinical care and research in nephrology.